Last reviewed · How we verify
NCT06351293
A Comparative Analysis of Two Hyaluronic Acid Fillers for Nasolabial Fold Correction
NA trial testing Defyne Treatment in Nasolabial Fold in Wrinkle in 15 participants. Completed in 30 April 2025.
17 March 2025
Quick facts
| Lead sponsor | Galderma R&D |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 21 February 2024 |
| Primary completion | 17 March 2025 |
| Estimated completion | 30 April 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Defyne Treatment in Nasolabial Fold
- RHA3 Treatment in Nasolabial Fold
Conditions studied
- Wrinkle — all drugs for Wrinkle →
Sponsor
Galderma R&D — full company profile →
Who can join
Adults 22 to 65, any sex, with Wrinkle. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized, split-face, subject-blinded, comparative study. Subjects will receive initial treatment with Defyne on one of the NLFs and with RHA3 on the other based on the pre-determined randomization. 4 weeks after the initial treatment, subjects will receive optional touch-up on one side or both sides at the Investigator's discretion for optimal correction. Subjects to return to the site at Month 3, 6, and 12 for follow-ups.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06351293
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Wrinkle
Currently open trials in the same condition.
- NCT06868615 — AVAVA MIRIA General Use · NA · recruiting
- NCT06571721 — The Effects of Topical Almond Oil and Tretinoin on Facial Wrinkles · NA · recruiting
- NCT06385171 — Assessing the Impact of Botulinum Toxin Type A on Facial Wrinkles: A Comprehensive Clinical Investigation · recruiting
- NCT06557434 — AV-23-001 AVAVA MIRIA Pilot Study · NA · active not recruiting
- NCT06202274 — Clinical Study to Evaluate the Safety and Efficacy of Candela Technology · NA · active not recruiting
Other Galderma R&D trials
Trials by the same sponsor.
- NCT07047690 — A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis · Phase 2 · recruiting
- NCT07344584 — A Prospective Pilot Study to Evaluate Safety and Effectiveness of GP0122 and GP0124 for Correction of Lines and Wrinkles · NA · not yet recruiting
- NCT07186413 — A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne · Phase 3 · recruiting
- NCT07398989 — A Clinical Study to Assess Efficacy and Tolerability of a Topical Skincare Product on Adults With Mature, Crepey Skin · Phase 4 · completed
- NCT06988618 — Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06351293 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Galderma R&D
- Last refreshed: 16 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06351293.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing